TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03150693
Drug: Pegylated L-Asparaginase
Normalized name: Pegylated dickeya chrysanthemi l-asparaginase
DrugBank: Pegcrisantaspase (DB16281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03150693
Drug: Thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01249352
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg, IV Weekly IV dose for up to 26 weeks.
Study: NCT01249352
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2, IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.
Study: NCT03994796
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00437619
Drug: calcipotriol hydrate [Daivonex]
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a \>50% response to Daivobet from weeks 0-4.
Study: NCT03994796
Drug: PI3K Inhibitor paxalisib
Normalized name: Fibrinolysis inhibitor
DrugBank: Paxalisib (DB15186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03994796
Drug: Entrectinib
Normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03994796
Drug: Adagrasib
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00640042
Drug: morphine sulfate extended release capsules
Normalized name: morphine sulfate Extended Release Oral Tablet
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
Study: NCT02852395
Drug: JNJ-48816274
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose; dose range of 5 mg up to 250 mg
Study: NCT01934660
Drug: Fludeoxyglucose F18
Normalized name: fludeoxyglucose F18
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01934660
Drug: 13N-amonia
Normalized name: ammonia (13N)
DrugBank: Ammonia (DB11118)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02486718
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
Study: NCT02486718
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.
Study: NCT02486718
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Study: NCT02486718
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
Study: NCT02486718
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive gemcitabine 1250 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.
Study: NCT02486718
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive pemetrexed 500 mg/m\^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
Study: NCT03727880
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Following standard of care neoadjuvant chemotherapy, subjects will receive two doses of pembrolizumab (200mg) IV 3 weeks apart prior to surgery. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 8 doses of pembrolizumab (200mg) IV 3 weeks apart.
Study: NCT02261285
Drug: ONO-4538
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03727880
Drug: Defactinib
Normalized name: Defactinib
DrugBank: Defactinib (DB12282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following 2 cycles of standard of care neoadjuvant chemotherapy, subjects will receive 400 mg defactinib twice a day up until 2 days preceding their surgery (approximately 6 weeks) during the immunotherapy cycles with pembrolizumab. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 400mg defactinib twice a day for 24 weeks.
Study: NCT01560585
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
Study: NCT01020747
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.
Study: NCT03592823
Drug: Hydroxychloroquine Sulfate 200 Mg Tablet
Normalized name: hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg, bidpo.
Study: NCT03028012
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants may be randomized to receive Lidocaine for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
Study: NCT03028012
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants may be randomized to receive Dexamethasone for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
Study: NCT01726517
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT04119050
Drug: M281
Normalized name: Immunoglobulin g1, anti-(human neonatal fc receptor) (human monoclonal m281 .gamma.-1 chain), disulfide with human monoclonal m281 .lambda.-chain, dimer
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M281 injection administered as intravenous infusion
Study: NCT00148135
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00148135
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03523442
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The participants will receive apalutamide 240 mg once daily orally.
Study: NCT04385433
Drug: EXPERIMENTAL ARM
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the experimental arm will receive:~* Daily pravastatin (40mg/d) during 12 months (pravastatin initiation: first day of radiotherapy).~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions).
Study: NCT03705533
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
Study: NCT03705533
Drug: Micardis
Normalized name: Micardis
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
Study: NCT01363297
Drug: Inotuzumab Ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m\^2 to 2.0 mg/m\^2.~Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m\^2.
Study: NCT04206488
Drug: JNJ-70033093
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-70033093 orally.
Study: NCT04206488
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive digoxin orally.
Study: NCT01993576
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery
Study: NCT03990519
Drug: JNJ-26366821
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).
Study: NCT03451851
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive a weight-based dose of guselkumab subcutaneously.
Study: NCT03451851
Drug: Placebo for guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.
Study: NCT03451851
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.
Study: NCT00702273
Drug: 150 µg Corifollitropin Alfa
Normalized name: peginterferon alfa-2b
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
Study: NCT00702273
Drug: Placebo for Corifollitropin Alfa
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
Study: NCT00702273
Drug: Placebo for RecFSH/Follitropin beta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
Study: NCT00702273
Drug: Ganirelix
Normalized name: Ganirelix
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
Study: NCT02920021
Drug: Etokimab
Normalized name: Etokimab
DrugBank: Etokimab (DB16661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanized monoclonal antibody, administered by intravenous infusion
Study: NCT00688077
Drug: Calcitonin
Normalized name: Calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
Study: NCT01536613
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device
Study: NCT04410354
Drug: Merimepodib
Normalized name: Merimepodib
DrugBank: Merimepodib (DB04862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg (total daily dose of 1200 mg) for 10 days
Study: NCT04410354
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg loading dose on Day 0 followed by 100 mg daily dose for 4 days. If a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)
Study: NCT02659384
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02659384
Drug: atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00136175
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00136175
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00136175
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04345783
Drug: Camrelizumab for injection, apatinib mesylate and tegio
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab for injection: fixed dose of 200 mg, ivgtt for 30 minutes, given on D1, repeat for every 3 weeks; Apatinib mesylate: 250 mg, p.o, qd; Tegio capsule: p.o., bid, D1-14, repeat for every 21 days.
Study: NCT03661307
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03661307
Drug: Quizartinib
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03661307
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02581930
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00801450
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg
Study: NCT00801450
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg
Study: NCT00260702
Drug: Omalizumab (Xolair)
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04273945
Drug: Macitentan 10 mg
Normalized name: macitentan 10 MG
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive macitentan 10 mg film-coated tablets orally.
Study: NCT02091297
Drug: TAP Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This intervention of a TAP block will be compared to the intervention of Common Care and to the intervention of Patient Controlled Epidural Analgesia
Study: NCT04273945
Drug: Macitentan 37.5 mg
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive macitentan 37.5 mg film-coated tablets orally.
Study: NCT02091297
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention of the Patient Controlled Epidural Analgesia will be compared to the intervention of a TAP block and the intervention of Common Care
Study: NCT02091297
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01024036
Drug: Siltuximab
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
Study: NCT02865135
Drug: DPX-E7 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A\*02 positive patients.
Study: NCT00574171
Drug: lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1250mg by mouth daily one hour before or after breakfast on a continuous basis.
Study: NCT04273945
Drug: Macitentan 75 mg
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive macitentan 75 mg film-coated tablets orally.
Study: NCT03882255
Drug: Ponesimod dose range (2 - 20 mg)
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive ponesimod oral tablet at a dose of 2 mg in Treatment period 1 and as an up-titrating regimen (dose range: 2mg-20mg) in Treatments period 2.
Study: NCT03882255
Drug: Placebo Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be administered placebo propranolol oral capsule from Day 1 to Day 19 in Treatment A of Treatment period 2.
Study: NCT02565888
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02565888
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02565888
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02565888
Drug: Cobicistat
Normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03882255
Drug: Propranolol 80 mg
Normalized name: propranolol 80 MG
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive propranolol 80 mg long acting oral capsule from Day 1 to Day 19 in Treatment B of Treatment period 2.
Study: NCT04271540
Drug: Tildrakizumab
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab, a p19 inhibitor which blocks IL-23 and Th17 mediated inflammation, will be given for 6 months. As below, a baseline cardiac PET scan and echocardiogram will be performed prior to initiation and after 6 months of treatment.~Radiation: A cardiac PET scan will be performed at baseline and at 6 months~Other cardiac Imaging: An echocardiogram will be performed at baseline and at 6-months.
Study: NCT00796614
Drug: tamsulosin hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT02016664
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The St.Joseph's Heath Care Pharmacy will supply the compounded oral ketamine capsules. Patients who are going to participate in this study are already taking this oral ketamine as a part of their chronic pain medications. No new patient will start oral ketamine for the sake of this study. Two doses of oral ketamine will be used for the same patient, 10 mg and 20 mg every 8 hours. These doses are the standard doses in our clinic. Other clinics using much higher doses.
Study: NCT02176356
Drug: bimatoprost ophthalmic solution 0.03%
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
Study: NCT00347737
Drug: teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide
Study: NCT01589523
Drug: Glycocholic Acid
Normalized name: Glycocholic acid
DrugBank: Glycocholic acid (DB02691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-15mg/kg body weight/day taken orally. Supplied as either liquid or 50mg capsules.
Study: NCT00020969
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02654899
Drug: PF-06815345
Normalized name: PF-06815345
DrugBank: PF-06815345 (DB14862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06815345 will be administered as a liquid dosage formulation
Study: NCT02654899
Drug: PF-06815345
Normalized name: PF-06815345
DrugBank: PF-06815345 (DB14862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation
Study: NCT02675998
Drug: Tenapanor
Normalized name: Tenapanor
DrugBank: Tenapanor (DB11761)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01703845
Drug: Tiotropium (high dose) + Olodaterol
Normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium + Olodaterol solution for inhalation
Study: NCT01703845
Drug: Tiotropium (low dose) + Olodaterol
Normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium + Olodaterol solution for inhalation
Study: NCT00043186
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab for subcutaneous injection
Study: NCT00043186
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 70 mg tablets
Study: NCT00513058
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose level (DL) 1 : 750 mg/d DL2, DL3, DL4: 1000 mg/d DL5, DL7, DL8: 1250 mg/d DL6: 1500 mg/d
Study: NCT00513058
Drug: vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DL1, DL2: 20 mg/m2 DL3: 22.5 mg/m2 DL4, DL5, DL6: 25 mg/m2 DL7: 27.5 mg/m2 DL8: 30 mg/m2
Study: NCT00121446
Drug: tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00121446
Drug: enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00121446
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00369603
Drug: Aricept
Normalized name: Aricept
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-weeks 5mg. Aricept and a subsequent 4-weeks of 10mg. Aricept
Study: NCT00157690
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 mg 1x weekly for 12 months